Clinical Trial Update: Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy) [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 pediatric trial is evaluating autologous HuCART19 T cells produced with the CliniMACS Prodigy platform for B-cell acute lymphoblastic leukemia and B…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia
• B-lineage Lymphoblastic Lymphoma

Drugs mentioned

• huCART19 Prodigy (HuCART19 CAR-T cells)

Snippet

Sponsor: Stephan Grupp MD PhD | Conditions: B Cell Acute Lymphoblastic Leukemia (B-ALL), B Lineage Lymphoblastic Lymphoma | Phase 1, Phase 2 | Status: RECRUITING